Compare CREG & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CREG | SNTI |
|---|---|---|
| Founded | N/A | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 24.5M |
| IPO Year | 2019 | 2021 |
| Metric | CREG | SNTI |
|---|---|---|
| Price | $0.34 | $0.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | ★ 4.7M | 101.8K |
| Earning Date | 03-27-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $867,431.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $150.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12953.89 | N/A |
| 52 Week Low | $0.20 | $0.80 |
| 52 Week High | $2.66 | $5.10 |
| Indicator | CREG | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 17.24 | 42.51 |
| Support Level | $0.20 | $0.80 |
| Resistance Level | $1.47 | $1.02 |
| Average True Range (ATR) | 0.26 | 0.05 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 5.21 | 28.72 |
Smart Powerr Corp is a pioneer in waste energy recycling and a developer of energy efficiency solutions for various energy-intensive industries in China. It uses the Build-Operate-Transfer (BOT) model to provide energy-saving and recovery facilities for multiple energy-intensive industries in China. Its waste energy recycling projects allow customers which use substantial amounts of electricity to recapture previously wasted pressure, heat, and gas from their manufacturing processes to generate electricity. The company offers waste energy recycling systems to companies for use in nonferrous metal plants. It constructs its projects at its customer's facility and the electricity produced is used on-site by the customer.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.